Epigenetic silencing of PDLIM4 promotes colorectal cancer by impairing BTF3 autophagic degradation and activating PI3K/Akt signalling
Clinical and Translational Medicine · 2026-11 · 16 (11)
DOI: 10.1002/ctm2.70882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 30.10.2026. Verfasst von Jiaxing Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory of Digestive Health; National Clinical …. Hauptthemen laut MEDLINE: Colorectal Neoplasms, LIM Domain Proteins, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Epigenetic silencing of tumour suppressor genes is a pivotal early event in colorectal cancer (CRC) pathogenesis. PDZ and LIM Domain 4 (PDLIM4) is a member of the PDZ‐LIM family with context‐dependent roles in tumour progression across different malignancies. However, its specific role and epigenetic regulation in colorectal cancer (CRC) remain elusive.
Methods
We integrated multi‐omics datasets and clinical cohorts to evaluate PDLIM4 expression and promoter methylation. Stool DNA was analyzed to assess the feasibility of non‐invasive detection of PDLIM4 promoter methylation. PDLIM4 knockout and overexpression cell lines were constructed to perform functional assays including proliferation, apoptosis, and stemness. In vivo experiments were validated utilizing xenograft mice or an azoxymethane (AOM)/ dextran sulphate sodium salt (DSS) CRC mouse model with intestinal epithelial cell‐specific overexpression of PDLIM4. Mechanistic investigations were conducted using coimmunoprecipitation coupled with mass spectrometry, RNA sequencing, ChIP‐qPCR and pharmacological rescue experiments.
Results
We identified a progressive loss of PDLIM4 protein along the normal‐adenoma‐carcinoma sequence, driven by DNMT3A‐mediated promoter hypermethylation, and lower PDLIM4 expression was associated with adverse patient prognosis. PDLIM4 methylation was also significantly increased in stool DNA from CRC patients compared with healthy controls. Mechanistically, genetic ablation of PDLIM4 significantly blunted the therapeutic efficacy of the DNA demethylating agent 5‐Azacytidine against CRC. Functionally, PDLIM4 restoration suppressed CRC cell proliferation and stemness while enhancing apoptosis in vitro, and reduced tumour growth in both AOM/DSS and xenograft models in vivo. At the molecular level, PDLIM4 interacted with BTF3 and promoted its autophagic‐lysosomal degradation, thereby limiting PI3K/Akt signalling, with NTRK2 identified as a potential transcriptional target linking BTF3 to PI3K/Akt activation.
Conclusion
DNMT3A‐mediated silencing of PDLIM4 is an early epigenetic event that facilitates CRC progression. PDLIM4 suppresses tumour growth by promoting BTF3 degradation, thereby restricting PI3K/Akt signalling. Thus, PDLIM4 methylation may have potential as a biomarker for early CRC detection. Key points DNMT3A‐mediated PDLIM4 promoter hypermethylation is an early event in colorectal tumorigenesis. Restoring PDLIM4 suppresses CRC proliferation and stemness while promoting apoptosis in vitro and in vivo. PDLIM4 promotes the autophagic‐lysosomal degradation of BTF3 and restrains PI3K/Akt signalling. Stool DNA analysis supports the potential of PDLIM4 methylation as a non‐invasive CRC biomarker
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory of Digestive Health; National Clinical Research Center for Digestive Disease, Beijing Key Laboratory of Early…
ORCID-Profile: Chuan-Guo Guo, Shutian Zhang, Peng Li, Si Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Guo, C. G., Qi, L., Hou, S., Lin, B., Ye, T., Zong, Y., Zhang, S., Zhang, N., Li, P., & Liu, S. (2026). Epigenetic silencing of PDLIM4 promotes colorectal cancer by impairing BTF3 autophagic degradation and activating PI3K/Akt signalling. Clinical and Translational Medicine, 16(11). https://doi.org/10.1002/ctm2.70882
Vancouver
Wang J, Guo CG, Qi L, Hou S, Lin B, Ye T, et al. Epigenetic silencing of PDLIM4 promotes colorectal cancer by impairing BTF3 autophagic degradation and activating PI3K/Akt signalling. Clinical and Translational Medicine. 2026;16(11). doi:10.1002/ctm2.70882
BibTeX
@article{Wang2026,
author = {Wang, Jiaxing and Guo, Chuan-Guo and Qi, Lingyu and Hou, Songyuan and Lin, Boshen and Ye, Tong and Zong, Ye and Zhang, Shutian and Zhang, Nan and Li, Peng and Liu, Si},
title = {Epigenetic silencing of PDLIM4 promotes colorectal cancer by impairing BTF3 autophagic degradation and activating PI3K/Akt signalling},
journal = {Clinical and Translational Medicine},
year = {2026},
volume = {16},
number = {11},
doi = {10.1002/ctm2.70882}
}
EUVIMED